Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
作者： Nick J. Dibb , Stephen M. Dilworth , Clifford D. Mol
DOI: 10.1038/NRC1434
关键词:
摘要: The cytoplasmic serine/threonine kinase BRAF and receptor tyrosine kinases of the platelet-derived growth factor (PDGFR) family are frequently activated in cancer by mutations an equivalent amino acid. Structural studies have provided important insights into why these very different share similar oncogenic hot spots PDGFR juxtamembrane region is also a frequent target. This research has implications for other that mutated human tumours treatment using inhibitors.
nature.com
sci-hub.se 参考文章(87)
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
Lisa Sarran, Peter Besmer, Ronald P DeMatteo, Sylvia J Tschernyavsky, Marc Ladanyi, Robert Maki, Mark Robson, Elyn Riedel, James M Woodruff, Murray F Brennan, Cristina R Antonescu, Gunhild Sommer, Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research. ,vol. 9, pp. 3329- 3337 ,(2003)
H Kitayama, Y Kanakura, T Furitsu, T Tsujimura, K Oritani, H Ikeda, H Sugahara, H Mitsui, Y Kanayama, Y Kitamura, Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. ,vol. 85, pp. 790- 798 ,(1995) , 10.1182/BLOOD.V85.3.790.BLOODJOURNAL853790
GM Morley, M Uden, WJ Gullick, NJ Dibb, Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene. ,vol. 18, pp. 3076- 3084 ,(1999) , 10.1038/SJ.ONC.1202646
Leanne E. Wybenga-Groot, Berivan Baskin, Siew Hwa Ong, Jiefei Tong, Tony Pawson, Frank Sicheri, Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region Cell. ,vol. 106, pp. 745- 757 ,(2001) , 10.1016/S0092-8674(01)00496-2
Heikki Joensuu, Christopher Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter Roberts, George Demetri, Management of malignant gastrointestinal stromal tumours. Lancet Oncology. ,vol. 3, pp. 655- 664 ,(2002) , 10.1016/S1470-2045(02)00899-9
Tomasz Skorski, Oncogenic tyrosine kinases and the dna-damage response Nature Reviews Cancer. ,vol. 2, pp. 351- 360 ,(2002) , 10.1038/NRC799
Alicia A. Russo, Philip D. Jeffrey, Nikola P. Pavletich, Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Structural & Molecular Biology. ,vol. 3, pp. 696- 700 ,(1996) , 10.1038/NSB0896-696
Philip D. Jeffrey, Alicia A. Russo, Kornelia Polyak, Emma Gibbs, Jerard Hurwitz, Joan Massagué, Nikola P. Pavletich, Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature. ,vol. 376, pp. 313- 320 ,(1995) , 10.1038/376313A0
Derek L. Stirewalt, Jerald P. Radich, The role of FLT3 in haematopoietic malignancies Nature Reviews Cancer. ,vol. 3, pp. 650- 665 ,(2003) , 10.1038/NRC1169